Printer Friendly

SPECTRUM DIAGNOSTICS AND BOEHRINGER MANNHEIM GMB: A RELATIONSHIP WITH A FUTURE

 ST. PAUL, Minn., Feb. 17 /PRNewswire/ -- Spectrum Diagnostics S.p.A. (NASDAQ: SPDIF) (soon to be Quantech Ltd.) is pleased to announce that they have successfully completed Stage I of development of their worldwide patented Surface Plasmon Resonance (SPR) technology with their strategic partner Boehringer Mannheim Gmb of Germany. Meeting at Spectrum's new facility in St. Paul on Feb. 12-13, 1993, Dr. Schmidt of Boehringer indicated his organization's intent to move immediately forward into Phase II of the development project. Boehringer will be an active participant during the next several months, contributing extensive proprietary and technical data to the project. This phase will be completed by the end of April 1993 at which time Spectrum and Boehringer will move forward to create an even closer relationship between the two organizations. Dr. Robert McKiel, vice president of R&D at Spectrum expressed his enthusiasm as to the eventual culmination of the project. When asked, he indicated that, "We at Spectrum are most pleased with the assistance and support provided to us by Boehringer Mannheim, and we feel that together we will be able to accomplish the goals of this next phase of work." At the completion of Phase II, Spectrum Diagnostics and Boehringer Mannheim will move to Phase III, which will culminate in providing a commercially viable diagnostic instrument with associated test disposables to the $21 billion medical diagnostic marketplace.
 Boehringer Mannheim Gmb is a privately owned multi-billion dollar medical company and is one of the largest suppliers of diagnostic instruments and disposables in the world. They have extensive sales and distribution networks in all of the world's major medical markets.
 -0- 2/17/93
 /CONTACT: Jill Miller, company relations manager for Spectrum, 612-647-6370/
 (SPDIF)


CO: Spectrum Diagnostics Corporation ST: Minnesota IN: MTC SU: JVN

KH -- MN009 -- 7384 02/17/93 13:28 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 17, 1993
Words:303
Previous Article:WARNER BROS. TOPS LIST OF DISTRIBUTORS HONORED, WITH 18 ACADEMY AWARD NOMINATIONS
Next Article:CLAYTON, DUBILIER & RICE AND VKM MANAGEMENT COMPLETE PURCHASE OF VAN KAMPEN MERRITT FROM XEROX
Topics:


Related Articles
BOEHRINGER MANNHEIM AND GENSIA ANNOUNCE COLLABORATION
IRIS AND BOEHRINGER MANNHEIM ANNOUNCE JOINT DEVELOPMENT OF HIGH-CAPACITY URINE ANALYZER
PERSEPTIVE BIOSYSTEMS NAMES SHAUN C. LONERGAN, FORMERLY OF BOEHRINGER MANNHEIM, AS SENIOR DIRECTOR, CORPORATE DEVELOPMENT
Lehman Millet Wins Biggest Diagnostics Account in its 18-Year History
IGEN Receives Royalty Advance From Boehringer Mannheim
Technical Chemicals & Products Completes $50+ Million Marketing Agreement For Product Sales In Latin America
IGEN Files A Complaint Against Boehringer Mannheim
Premier Announces Corporate Partnerships With Bayer Health Care Partners, Boehringer Mannheim Corporation, and 3M Health Care
Premier Adds Boehringer Mannheim Corporation to Corporate Partner Program
IGEN Wins Injunction Against Roche-Boehringer Mannheim

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters